Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01412229 · ClinicalTrials.gov registry record · Phase 2
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
A Phase 2 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT01412229 is a Phase 2 study that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 40 participants.
The verdict
NCT01412229, a Phase 2 study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgical definitive therapy.
Interventions
- DRUG Carboplatin
- DRUG Cetuximab
- DRUG Nab-paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-02 |
| Est. Completion | 2019-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01412229
The ClinicalTrials.gov registry entry for NCT01412229 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT01412229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01412229 about?
NCT01412229 is a clinical study titled "Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck". This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgical definitive therapy.
What is the current status of trial NCT01412229?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2012-02. Estimated completion is 2019-12.
What interventions are being tested in trial NCT01412229?
The interventions under investigation include: Carboplatin (DRUG), Cetuximab (DRUG), Nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT01412229?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.